Table 1.
Center | IA | Median dose | Observational | MT+IA | AC MT in study period | % | Typical mode of intra-arterial administration |
|||
---|---|---|---|---|---|---|---|---|---|---|
Microcatheter injection | Localization of microcatheter | Speed of injection | Control series (time point) | |||||||
University Hospital Bochum | tPA | 8 (4–18) mg | 01/2011–05/2019 | 11 | 1,020 | 1 | Yes | As distal as safely possible, usually before clot | 1 mL/min | One control run 10 min after final injection |
University Hospital Helsinki | tPA | 3 (2–5) mg | 01/2016–10/2019 | 31 | 770 | 4.0 | Yes | As distal as safely possible, usually before clot | Small boluses of 1 mg/5 min | Control run after each 1 mg bolus (usually at 5 min after injection) |
University Hospital Bern | UK | 250.000 (250.000–500.000) IU | 01/2010–12/2018 | 117 | 1,195 | 9.8 | Yes | As distal as safely possible, usually before clot | Full dose over 30 min using a syringe infusion pump. | Immediately after infusion is finished, no additional control run |
University Hospital Strasbourg | tPA | 11 (10–15) mg | 01/2018–01/2019 | 28 | 142 | 19.7 | Yes | As distal as safely possible | 5 mL/min injection by hand using a 5 mL syringe | Immediately after infusion is finished, no additional control run |
University Hospital Essen | tPA | 10 (5–10) mg | 01/2015–09/2019 | 13 | 380 | 3.4 | Yes | Proximal infusion (M1) in case of M3/M4 | 5 mL/min injection by hand using a 5 mL syringe | Immediately after infusion is finished, no additional control run |
Otherwise as distal as possible | ||||||||||
University Hospital Münster | tPA | 10 (7–18) mg | 01/2015–12/2016 | 4 | 216 | 1.9 | Yes | As distal as safely possible | 5 mL/min injection by hand using a 5 mL syringe | Immediately after infusion is finished, no additional control run |
University Hospital Köln | tPA | 7 (5–10) mg | 01/2018–10/2019 | 76 | 270 | 28.1 | n=31 (administration via microcatheter) | Microcatheter: As distal as possible usually before clot | 1 mL/min injection by hand using a 10 mL syringe | Immediately after infusion is finished, no additional control run |
n=45 (administration via distal access catheter) | Distal access: proximal infusion (usually M1 for e.g., residual M3 occlusion) | |||||||||
University Hospital Göttingen | tPA | 11 (9–18) mg | 01/2016–08/2019 | 13 | 577 | 2.3 | Yes | As distal as safely possible (usually just before clot) | 0.5–1 mL/min injection by hand using multiple 1 mL syringes | Immediately after infusion is finished, no additional control run |
University Hospital Hamburg | tPA | 10 (10–18) mg | 01/2015–01/2018 | 5 | 762 | 0.7 | Yes | As distal as safely possible (usually just before clot) | 1 mL/min injection by hand using multiple 1 mL syringes | Immediately after infusion is finished, no additional control run |
University Hospital Rostock | tPA | 18 (9–20) mg | 10/2015–10/2019 | 13 | 280 | 4–6 | Yes | Proximal Infusion (e.g., M1 for an residual M3 occlusion) | 5 mL/min injection by hand using a 5 mL syringe | Immediately after infusion is finished, no additional control run |
Total | 311 | 5,612 | 5.5 |
M1, M3, M4, first, third and fourth segment of the middle cerebral artery, respectively.
MT, mechanical thrombectomy; IA, intra-arterial; IQR, interquartile range; AC, anterior circulation; tPA, tissue plasminogen activator; UK, urokinase.